Post-translational modifications of PML: Consequences and implications

Xiwen Cheng, Hung Ying Kao

研究成果: Review article

29 引文 (Scopus)

摘要

The tumor suppressor promyelocytic leukemia protein (PML) predominantly resides in a structurally distinct sub-nuclear domain called PML nuclear bodies. Emerging evidences indicated that PML actively participates in many aspects of cellular processes, but the molecular mechanisms underlying PML regulation in response to stress and environmental cues are not complete. Post-translational modifications, such as SUMOylation, phosphorylation, acetylation, and ubiquitination of PML add a complex layer of regulation to the physiological function of PML. In this review, we discuss the fast-moving horizon of post-translational modifications targeting PML.

原文English
文章編號Article 00210
期刊Frontiers in Oncology
2 JAN
DOIs
出版狀態Published - 2013 十二月 24

指紋

Post Translational Protein Processing
Sumoylation
Tumor Suppressor Proteins
Ubiquitination
Acetylation
Promyelocytic Leukemia Protein
Cues
Phosphorylation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

引用此文

@article{8dc4a814addf4b06a7d265e7697d1a94,
title = "Post-translational modifications of PML: Consequences and implications",
abstract = "The tumor suppressor promyelocytic leukemia protein (PML) predominantly resides in a structurally distinct sub-nuclear domain called PML nuclear bodies. Emerging evidences indicated that PML actively participates in many aspects of cellular processes, but the molecular mechanisms underlying PML regulation in response to stress and environmental cues are not complete. Post-translational modifications, such as SUMOylation, phosphorylation, acetylation, and ubiquitination of PML add a complex layer of regulation to the physiological function of PML. In this review, we discuss the fast-moving horizon of post-translational modifications targeting PML.",
author = "Xiwen Cheng and Kao, {Hung Ying}",
year = "2013",
month = "12",
day = "24",
doi = "10.3389/fonc.2012.00210",
language = "English",
volume = "2 JAN",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

Post-translational modifications of PML : Consequences and implications. / Cheng, Xiwen; Kao, Hung Ying.

於: Frontiers in Oncology, 卷 2 JAN, Article 00210, 24.12.2013.

研究成果: Review article

TY - JOUR

T1 - Post-translational modifications of PML

T2 - Consequences and implications

AU - Cheng, Xiwen

AU - Kao, Hung Ying

PY - 2013/12/24

Y1 - 2013/12/24

N2 - The tumor suppressor promyelocytic leukemia protein (PML) predominantly resides in a structurally distinct sub-nuclear domain called PML nuclear bodies. Emerging evidences indicated that PML actively participates in many aspects of cellular processes, but the molecular mechanisms underlying PML regulation in response to stress and environmental cues are not complete. Post-translational modifications, such as SUMOylation, phosphorylation, acetylation, and ubiquitination of PML add a complex layer of regulation to the physiological function of PML. In this review, we discuss the fast-moving horizon of post-translational modifications targeting PML.

AB - The tumor suppressor promyelocytic leukemia protein (PML) predominantly resides in a structurally distinct sub-nuclear domain called PML nuclear bodies. Emerging evidences indicated that PML actively participates in many aspects of cellular processes, but the molecular mechanisms underlying PML regulation in response to stress and environmental cues are not complete. Post-translational modifications, such as SUMOylation, phosphorylation, acetylation, and ubiquitination of PML add a complex layer of regulation to the physiological function of PML. In this review, we discuss the fast-moving horizon of post-translational modifications targeting PML.

UR - http://www.scopus.com/inward/record.url?scp=84885626870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885626870&partnerID=8YFLogxK

U2 - 10.3389/fonc.2012.00210

DO - 10.3389/fonc.2012.00210

M3 - Review article

AN - SCOPUS:84885626870

VL - 2 JAN

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 00210

ER -